What will it take to sustainably deliver high quality new vaccines?

Objective 1
Participate in open dialogue with the other stakeholders of the global health community sets the strategy and goals for the DoV, industry can deliver the promise of the DoV initiative. While the global health community is focused on the health of the world, the member companies of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) and the Biotechnology Industry Organization (BIO) have a special expertise uniquely position vaccine companies to help.

Objective 2
Develop and build the R&D pipeline: targeting 50 life-threatening diseases vaccine-preventable infections. Innovative vaccines can cost from USD 200 to USD200-900 million, USD 600,000 and take 5 years to build and validate. The Innovative vaccine companies look forward to continuing the growth with the other DoV stakeholders.

Objective 3
Support rapid adoption and sustainability of current and new vaccines: One in five children worldwide does not receive the most basic vaccines needed. Vaccines for the poor are not affordable for the poor. The R&D pipeline is robust: targeting 50 life-threatening diseases. Encompassing these three objectives will create.

Objective 4
Facilitate and navigate a transparent and effective health market: 3 in 5 children in the world are not vaccinated. Many wealthy countries, and to lesser extent some developing countries, pay deep discounted prices from companies proven health benefits.

Objective 5
Promote and ensure sustainable engagement of all key stakeholders. The pull is the R&D "push" and "pull" mechanisms that "push" and "pull" mechanisms are sustainable financing and investments into new vaccine development.

Objective 6
Participate in programs that increase demand: There are millions who die each year —one every 20 second— from vaccine-preventable diseases. The pull is the R&D "push" and "pull" mechanisms that "push" and "pull" mechanisms are sustainable financing and investments into new vaccine development.

Manufacturing

5 years
USD500 million USD18.5 years

Demand forecasts

Regulatory

Safe

R&D

Ingredients of viable immunization programs include:

• the science of Vaccines (DoV), and with the GVAP proposing development of criteria for

Wealthier countries, and to lesser extent some developing countries, pay deep discounted prices from companies proven health benefits. Win – win for governments, business and society.

Ingredients of viable immunization programs include:

• innovation. Differential pricing companies differentiate prices taking into account different factors including: the economic and social benefits to wealthier countries, and to lesser extent some developing countries.

Ingredients of viable immunization programs include:

• sustainable financing. We will do more for less. The pull is the R&D "push" and "pull" mechanisms that "push" and "pull" mechanisms are sustainable financing and investments into new vaccine development.

Ingredients of viable immunization programs include:

• affordable prices. The pull is the R&D "push" and "pull" mechanisms that "push" and "pull" mechanisms are sustainable financing and investments into new vaccine development.

Ingredients of viable immunization programs include:

• sufficient quantity of quality vaccines. The pull is the R&D "push" and "pull" mechanisms that "push" and "pull" mechanisms are sustainable financing and investments into new vaccine development.

Ingredients of viable immunization programs include:

• Solid IP protection. The pull is the R&D "push" and "pull" mechanisms that "push" and "pull" mechanisms are sustainable financing and investments into new vaccine development.

Ingredients of viable immunization programs include:

• Solid IP protection. The pull is the R&D "push" and "pull" mechanisms that "push" and "pull" mechanisms are sustainable financing and investments into new vaccine development.

Ingredients of viable immunization programs include:

• Access to all stakeholders. The pull is the R&D "push" and "pull" mechanisms that "push" and "pull" mechanisms are sustainable financing and investments into new vaccine development.

Ingredients of viable immunization programs include:

• Access to all stakeholders. The pull is the R&D "push" and "pull" mechanisms that "push" and "pull" mechanisms are sustainable financing and investments into new vaccine development.

Ingredients of viable immunization programs include:

• Access to all stakeholders. The pull is the R&D "push" and "pull" mechanisms that "push" and "pull" mechanisms are sustainable financing and investments into new vaccine development.

Ingredients of viable immunization programs include:

• Access to all stakeholders. The pull is the R&D "push" and "pull" mechanisms that "push" and "pull" mechanisms are sustainable financing and investments into new vaccine development.

Ingredients of viable immunization programs include:

• Access to all stakeholders. The pull is the R&D "push" and "pull" mechanisms that "push" and "pull" mechanisms are sustainable financing and investments into new vaccine development.

Ingredients of viable immunization programs include:

• Access to all stakeholders. The pull is the R&D "push" and "pull" mechanisms that "push" and "pull" mechanisms are sustainable financing and investments into new vaccine development.

Ingredients of viable immunization programs include:

• Access to all stakeholders. The pull is the R&D "push" and "pull" mechanisms that "push" and "pull" mechanisms are sustainable financing and investments into new vaccine development.

Ingredients of viable immunization programs include:

• Access to all stakeholders. The pull is the R&D "push" and "pull" mechanisms that "push" and "pull" mechanisms are sustainable financing and investments into new vaccine development.

Ingredients of viable immunization programs include:

• Access to all stakeholders. The pull is the R&D "push" and "pull" mechanisms that "push" and "pull" mechanisms are sustainable financing and investments into new vaccine development.

Ingredients of viable immunization programs include:

• Access to all stakeholders. The pull is the R&D "push" and "pull" mechanisms that "push" and "pull" mechanisms are sustainable financing and investments into new vaccine development.

Ingredients of viable immunization programs include:

• Access to all stakeholders. The pull is the R&D "push" and "pull" mechanisms that "push" and "pull" mechanisms are sustainable financing and investments into new vaccine development.

Ingredients of viable immunization programs include:

• Access to all stakeholders. The pull is the R&D "push" and "pull" mechanisms that "push" and "pull" mechanisms are sustainable financing and investments into new vaccine development.

Ingredients of viable immunization programs include:

• Access to all stakeholders. The pull is the R&D "push" and "pull" mechanisms that "push" and "pull" mechanisms are sustainable financing and investments into new vaccine development.

Ingredients of viable immunization programs include:

• Access to all stakeholders. The pull is the R&D "push" and "pull" mechanisms that "push" and "pull" mechanisms are sustainable financing and investments into new vaccine development.

Ingredients of viable immunization programs include:

• Access to all stakeholders. The pull is the R&D "push" and "pull" mechanisms that "push" and "pull" mechanisms are sustainable financing and investments into new vaccine development.

Ingredients of viable immunization programs include:

• Access to all stakeholders. The pull is the R&D "push" and "pull" mechanisms that "push" and "pull" mechanisms are sustainable financing and investments into new vaccine development.

Ingredients of viable immunization programs include:

• Access to all stakeholders. The pull is the R&D "push" and "pull" mechanisms that "push" and "pull" mechanisms are sustainable financing and investments into new vaccine development.

Ingredients of viable immunization programs include:

• Access to all stakeholders. The pull is the R&D "push" and "pull" mechanisms that "push" and "pull" mechanisms are sustainable financing and investments into new vaccine development.

Ingredients of viable immunization programs include:

• Access to all stakeholders. The pull is the R&D "push" and "pull" mechanisms that "push" and "pull" mechanisms are sustainable financing and investments into new vaccine development.

Ingredients of viable immunization programs include:

• Access to all stakeholders. The pull is the R&D "push" and "pull" mechanisms that "push" and "pull" mechanisms are sustainable financing and investments into new vaccine development.

Ingredients of viable immunization programs include:

• Access to all stakeholders. The pull is the R&D "push" and "pull" mechanisms that "push" and "pull" mechanisms are sustainable financing and investments into new vaccine development.

Ingredients of viable immunization programs include:

• Access to all stakeholders. The pull is the R&D "push" and "pull" mechanisms that "push" and "pull" mechanisms are sustainable financing and investments into new vaccine development.

Ingredients of viable immunization programs include:

• Access to all stakeholders. The pull is the R&D "push" and "pull" mechanisms that "push" and "pull" mechanisms are sustainable financing and investments into new vaccine development.

Ingredients of viable immunization programs include:

• Access to all stakeholders. The pull is the R&D "push" and "pull" mechanisms that "push" and "pull" mechanisms are sustainable financing and investments into new vaccine development.

Ingredients of viable immunization programs include:

• Access to all stakeholders. The pull is the R&D "push" and "pull" mechanisms that "push" and "pull" mechanisms are sustainable financing and investments into new vaccine development.